{"id":"NCT04664959","sponsor":"Samsung Bioepis Co., Ltd.","briefTitle":"A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis","officialTitle":"A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Compare the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Between SB16 (Proposed Denosumab Biosimilar) and Prolia® in Postmenopausal Women With Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-26","primaryCompletion":"2022-06-20","completion":"2023-01-03","firstPosted":"2020-12-11","resultsPosted":"2025-01-09","lastUpdate":"2025-02-04"},"enrollment":457,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"SB16 (Proposed Denosumab Biosimilar)","otherNames":[]},{"type":"DRUG","name":"Prolia® (Denosumab)","otherNames":[]}],"arms":[{"label":"SB16 (Proposed Denosumab Biosimilar)","type":"EXPERIMENTAL"},{"label":"Prolia® (Denosumab)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomised, double-blind, multicentre study to evaluate the efficacy, safety, PK, PD, and immunogenicity of SB16 compared to Prolia® in postmenopausal women with osteoporosis.","primaryOutcome":{"measure":"Percent Change From Baseline in Lumbar Spine BMD at Month 12","timeFrame":"Baseline and Month 12","effectByArm":[{"arm":"SB16","deltaMin":5.63,"sd":0.25},{"arm":"Prolia","deltaMin":5.3,"sd":0.254}],"pValues":[]},"eligibility":{"minAge":"55 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":5,"countries":["Poland"]},"refs":{"pmids":["39243386"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":225},"commonTop":["Hypocalcaemia","COVID-19","Arthralgia","Nasopharyngitis","Headache"]}}